We have concluded a joint research and development agreement with Miura Co., Ltd.

Commencement of Joint Research for the Provision of HCPT for Medical Devices and Medical Materials

MiCAN Technologies Co., Ltd. (Head Office: Kyoto City, Kyoto Prefecture, President: Kazuo Miyazaki) has started joint research with Miura Co., Ltd. (Tokyo Head Office: Minato-ku, Tokyo, President: Tsuyoshi Yoneda) from May 1, 2024, with the aim of improving and evaluating the usefulness of an evaluation system using our established and owned Mylc®, to construct an in vitro human cell-based pyrogen test (HCPT*) targeting medical devices and medical materials.
*HCPT: Human-Cell based Pyrogen Test

Rare Immature Myeloid Cells

We have developed and are selling Mylc, a technology that enables the “massive, stable, and continuous” provision of human myeloid cells, which play a crucial role in infectious diseases and immune system disorders. Mylc have excellent immune responses, and leveraging this characteristic, we are developing evaluation kits for functional materials. These cell products not only detect pyrogenic substances, as in this joint research, but also offer high reproducibility for those conducting research and development of drugs and vaccines or studying the immune system.

Click here for the press release (PDF version).

Inquiries Regarding This Joint Research
MiCAN Technologies Co., Ltd.
info2@micantechnologies.com